Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of VelosBio.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
VelosBio
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
11045 Roselle Street, Suite 130 San Diego CA 92121
Telephone
Telephone
+1 (858) 461-6666
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Acquisition strengthens merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate to treat hematological malignancies and solid tumors.


Lead Product(s): VLS-101

Therapeutic Area: Oncology Product Name: VLS-101

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: $2,750.0 million Upfront Cash: $2,750.0 million

Deal Type: Acquisition November 05, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Phase 2 trial will enroll patients with previously treated solid tumors. Patients will receive VLS-101 2.5 mg/kg intravenously once every three weeks for as long as they are safely benefiting from VLS-101 therapy.


Lead Product(s): VLS-101

Therapeutic Area: Oncology Product Name: VLS-101

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).


Lead Product(s): VLS-101

Therapeutic Area: Oncology Product Name: VLS-101

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types.


Lead Product(s): VLS-101

Therapeutic Area: Oncology Product Name: VLS-101

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Matrix Capital Management

Deal Size: $137.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing July 08, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY